In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Léa Sanchez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris F-75006, France. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Microbial Sensitivity Tests, Anti-Bacterial Agents, beta-Lactams. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Vaincre la Mucoviscidose, l'Association Grégory Lemarchal, l’Association Grégory Lemarchal.
Abstract (Originalsprache)
Objectives
Mycobacterium abscessus has emerged as an opportunistic pathogen responsible for lung infections, especially in cystic fibrosis patients. In spite of the production of the broad-spectrum β-lactamase BlaMab, the carbapenem imipenem is recommended in the initial phase of the treatment of pulmonary infections. Here, we determine whether the addition of vaborbactam, a second-generation β-lactamase inhibitor belonging to the boronate family, improves the activity of β-lactams against M. abscessus.
Methods
The activity of β-lactams, alone or in combination with vaborbactam, was evaluated against M. abscessus CIP104536 by determining MICs, time-killing and intramacrophage activity. Kinetic parameters for the inhibition of BlaMab by vaborbactam were determined by spectrophotometry.
Results
The combination of vaborbactam (8 mg/L) with β-lactams decreased more than 8 times the MIC of amoxicillin (from >1024 to 128 mg/L) and 2 times the MICs of meropenem (from 16 to 8 mg/L) and imipenem (from 4 to 2 mg/L). The reduction of the MICs was less than that obtained with avibactam at 4 mg/L for amoxicillin (from >1024 to 16 mg/L, more than 64 times less) and for meropenem (from 16 to 4 mg/L, 4 times less). In vitro and intracellularly, M. abscessus was not killed by the meropenem/vaborbactam combination, in spite of significant in vitro inhibition of BlaMab by vaborbactam.
Conclusions
Inhibition of BlaMab by vaborbactam decreases the MIC of β-lactams, including that of meropenem. As meropenem/vaborbactam is clinically available, this combination offers an alternative therapeutic option that should be evaluated for the treatment of pulmonary infections due to M. abscessus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris F-75006, France.
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Université Paris Cité, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris F-75015, France.
ORCID-Profile: Michel Arthur
Förderung
- Vaincre la Mucoviscidose
- l'Association Grégory Lemarchal
- l’Association Grégory Lemarchal
Zitieren
APA
Sanchez, L., Bitar, M., Herail, Q., Dorchêne, D., Hugonnet, J. E., Arthur, M., & Mainardi, J. L. (2024). In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae181
Vancouver
Sanchez L, Bitar M, Herail Q, Dorchêne D, Hugonnet JE, Arthur M, et al. In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae181
BibTeX
@article{Sanchez2024,
author = {Sanchez, Léa and Bitar, Maria and Herail, Quentin and Dorchêne, Delphine and Hugonnet, Jean-Emmanuel and Arthur, Michel and Mainardi, Jean-Luc},
title = {In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae181}
}
EUVIMED